Efficacy of 93 Cases of Recurrent Ovarian Cancer

Abstract

Objective To predict the recurrence of ovarian cancer (OC), to analyze the efficacy and prognosis of recurrent ovarian cancer (ROC) patients. Methods The clinical medical records of 93 ROC patients were retrospectively analyzed. Univariate analysis was performed on the influencing factors of disease free interval (DFI) in ROC patients. We evaluated the effect of different treatments on progression free survival (PFS) and overall survival (OS) after recurrence. Results The single factor analysis of DFI after initial treatment showed that tumor differentiation, clinical stage, residual tumor size after initial surgery, and the number of chemotherapy courses after initial surgery were related to DFI (P 150 U/L (P 3 (P < 0.05). Conclusion Pathological differentiation, clinical stage, the chemotherapy course and the size of residual tumor after initial cytoreductive surgery are associated with DFI in recurrent ovarian cancer. ROC patients with recurrent tumors number ≤ 3 or CA125 ≤ 150 U/L could benefit from SCS.

Keywords

• recurrent ovarian cancer
• secondary cytoreductive surgery
• disease free interval
• progression free survival
• overall survival after recurrence